COMMUNIQUÉS West-GlobeNewswire

Ultragenyx to Participate in Investor Conferences in December
24/11/2025
NOVATO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra [...]
Onco360® Has Been Selected as The National Specialty Pharmacy Partner for HYRNUO® (sevabertinib)
24/11/2025
LOUISVILLE, Ky., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Bayer Pharmaceuticals for HYRNUO ® (sevabertinib [...]
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
24/11/2025
Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studies One-time [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 octobre 2025
24/11/2025
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 octobre 2025 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, [...]
CARBIOS signe deux nouveaux engagements commerciaux pluriannuels de PET biorecyclé avec des acteurs majeurs de la boisson
24/11/2025
Clermont-Ferrand (France), 24 novembre 2025 (18h30 CET). CARBIOS (Euronext Growth Paris : ALCRB), annonce la signature de deux nouveaux engagements commerciaux pluriannuels avec des acteurs majeurs de la boisson, pour [...]
CARBIOS signs two new multi-year commercial agreements for recycled PET with major players in the beverage industry
24/11/2025
Clermont-Ferrand (France), 24 November 2025 (18h30 CET). CARBIOS (Euronext Growth Paris : ALCRB), announces the signing of two new multi-year commercial agreements with major players in beverage industry, for the supply [...]
Press release: Transparency Notification from Shareholders
24/11/2025
Ghent, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Transparency Notification from Shareholders Ghent, Belgium – 24 November 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer [...]
HealthLynked Engages NE Holdings, LLC to Lead Strategic Advisory Services for Nasdaq Listing
24/11/2025
NAPLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK ), a patient-centric healthcare technology company, announced today that it has entered into a Capital Market Advisory Agreement [...]
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
24/11/2025
Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu season SAN DIEGO, [...]
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
24/11/2025
CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and [...]
Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals
24/11/2025
Nanox’s HealthOST and HeathVCF recommended for use in UK National Health Service hospitals for a three-year period as the use of AI solutions in bone disease is evaluated PETACH TIKVA, Israel, Nov. 24, 2025 (GLOBE [...]
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality
24/11/2025
SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces [...]
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025
24/11/2025
Study evaluates Lumee™ Oxygen tissue monitoring platform with transcutaneous partial pressure of oxygen (tcpO ₂ ) in peripheral artery disease patients BERKELEY, Calif, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“ [...]
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
24/11/2025
November 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced today that the University of Bonn, Germany is now actively [...]
Imviva Biotech Announces Seven Presentations Highlighting its ANSWER™ Allogeneic CAR-T Platform at the 67th American Society of Hematology Annual Meeting
24/11/2025
Two oral, and five poster presentations will showcase the company’s progress in developing allogenic cell therapy candidates for multiple hematological malignancies CTD402 data for the treatment of T-ALL/LBL selected as [...]
Biotech Valuations Rise as New Clinical Platforms Show Progress
24/11/2025
AUSTIN, Texas, Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted Accounting Principles [...]
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs
24/11/2025
New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and [...]
CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
24/11/2025
Company to deliver a poster presentation on clinical data demonstrating sustained remission following immune checkpoint inhibitor therapy with or after leronlimab treatment in patients with metastatic or locally [...]
Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
24/11/2025
Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a highly aggressive, orphan hematologic [...]

Pages